BOULDER, CO--(Marketwire - March 14, 2011) -
N30 Pharmaceuticals LLC (N30 Pharma) today announced publication of a paper titled, "Discovery of S-Nitrosoglutathione Reductase Inhibitors: Potential Agents for the Treatment of Asthma and Other Inflammatory Diseases" in the Journal ACS Medicinal Chemistry Letter. This paper details the structure-based optimization of potent small molecule inhibitors of the enzyme S-nitrosoglutathione reductase (GSNOR). The report focuses on the lead chemical series which generated N30 N6022, a first in class GSNOR inhibitor currently in Phase 1b/2a trials for the treatment of asthma.
The publication can be accessed at: http://pubs.acs.org/journal/amclct
GSNOR breaks down S-nitrosoglutathione (GSNO), and as such is an important regulator of the body's pool of GSNO. In the lung, GSNO likely plays an important role in maintaining normal respiratory function through its influence on bronchial tone and anti-inflammatory effects. In asthmatics, GSNOR up-regulation and decreased GSNO levels have been shown to contribute to respiratory disease, and genetic variants of GSNOR have been correlated with disease susceptibility and poor response to therapy. GSNO has also been found to be important in the gastrointestinal and cardiovascular systems, as well as the regulating the control of breathing. GSNOR inhibitors are novel drug candidates, and represent a new approach to treating asthma and other inflammatory diseases.
